OxyPrem uses harmless light (more on NIRS) to determine absolute haemoglobin oxygen saturation in any human tissue.
OxyPrem offers a two-year sensor lifetime and high component quality, while substantially reducing waste.
With its excellent performance in repeated placement and its high reading certainty, OxyPrem achieves new levels in precision.
High component quality and advanced algorithms provide consistent readings, also across varying perfusion environments.
Due to OxyPrem's glue-free fixation, skin damage from adhesives is avoided.
Its very soft silicone hull is made for comfortable wear.
OxyPrem can be used in any patient at the risk of hypoxia and on any body part which is at least 30 mm thick.
Since OxyPrem is reusable, costs are reduced drastically when used routinely or over longer time periods.
Links to publications on OxyPrem and its predecessor devices:
1
,
2
,
3
,
4
April 2021
OxyPrem's CEO Alexander Nitsch will speak at FutureHealth's discussion table "How Swiss innovators are rethinking patient experience", together with Ancora.ai and Medisanté.
Date & time: Apr 28th, 15:00 CET. Link: here.
February 2021
OxyPrem will be present at this year's edition of Swiss Nordic Bio. We are looking forward to new contacts and interesting exchange of ideas!
See this link for further information. See you there!
February 2021
The OxyPrem team has secured a spot in Swissnex Boston's US East Coast Startup Bootcamp. This excellent 2-week programme provides lots of valuable resources for young companies intending to expand to the US markets.
Follow Swissnex in Boston and New York on LinkedIn to find out more.
November 2020
For the second time, OxyPrem was awarded the EU Seal of Excellence for outstanding projects.
Once again thank you to the EU!
November 2020
For the second consecutive year, OxyPrem will be present at Neonatal Emergencies organized by Poznan University of Medical Sciences. The event will take place online on November 27th and 28th and host several very interesting sessions.
Information and registration is available on the official website.
November 2020
Alexander Nitsch will be a guest speaker at the (online) Swiss Indian Entrepreneurship Day.
The official event link is here.
October 2020
Together with several other high-impact projects by Wyss Zurich, the OxyPrem team is happy to welcome you at the Wyss pavilion at the Startup Days on October 5th and 6th in Berne, Switzerland!
The official Startupdays website is www.startupdays.ch.
September 2020
Among numerous applicants, OxyPrem is happy to announce selection for the Market Discovery Camp Africa. The team is excited to get in touch with stakeholders from all over the African healthcare sector.
The official announcement is here.
August 2020
The European Union has written a feature article on OxyPrem. It is available in six languages via the following link: CLICK.
June 2020
OxyPrem's CEO Alexander Nitsch has been invited to speak at the upcoming Venture Briefing on June 3rd. The link to the event is here.
May 2020
OxyPrem was awarded the Seal of Excellence by the European Union's Accelerator program (SME Instrument phase II). This demonstrates that OxyPrem is among the top science startups in Europe.
Thank you to the EU for this strong encouragement!
February 2020
The OxyPrem team is attending the LSZ Cause of Health Conference at Technopark Zurich on February 3rd.
The entire team is looking forward to interesting conversations and exciting talks!
January 2020
OxyPrem will be present at the Investigators Meeting of the SafeBoosC-III study held in Copenhagen, Denmark.
The team is happy for the opportunity to meet the leading clinicians from the European neonatology field.
January 2020
OxyPrem will be present at the FutureHealth Basel 2020 held on January 28th. Please come and see us at our booth!
November 2019
OxyPrem will attend the Neonatal Emergencies Symposium in Poznan, Poland (details on neonate.eu.
It will be very interesting to exchange ideas with leading Polish and other European neonatologists.
November 2019
OxyPrem is pleased to announce that we have been selected for the 2019/2020 cohort of the St. Gallen University's AIT Brazil programme.
AIT (Academia-Industry Training) Brazil is a two-chapter programme which brings Brazilian and Swiss entrepreneurs together in on-site visits to both countries.
September 2019
The European Union is supporting OxyPrem by means of its Horizon 2020 SME instrument. Thank you to the EU for their support!
The OxyPrem application was selected for support under phase I of the SME instrument programme following a thorough review by the European Union.
October 2019
OxyPrem will have a booth at the Swiss Innovation Forum 2019 at Congress Center Basel on Nov 21st.
In its 14th installment, the SIF will the "annual dose of inspiration" to attendees from science, industry and public bodies.
September 2019
The OxyPrem 1.4 tissue oximeter system has obtained the CE mark.
Thus, OxyPrem 1.4 may now be used in professional clinical environments. Our entire team is glad to have achieved this big milestone!
August 2019
The OxyPrem team has successfully completed Venture Kick stage 3. After one year, the Venture Kick journey has come to an end and OxyPrem will receive an additional CHF 100'000.-- in funding.
The official announcement is here.
April 2019
OxyPrem and our friends from Prediva are the Swiss Winners of the 2018/19 Academia-Industry Training (AIT) India programme.
Thank you to all participants and to Venturelab!
Read more here and here.
February 2019
Wyss Zurich is a joint accelerator by University of Zurich and ETH Zurich, made possible by a generous donation by philantropist Dr. h.c. mult. Hansjörg Wyss.
Please visit our profile page here.
December 2018
The UZH Faculty of Medicine has received a considerable donation by Uniscientia Foundation. It will be used to support OxyPrem.
Thank you for the encouragement from the entire team!
November 2018
OxyPrem advances to Venture Kick stage II.
Thanks to the jury for the exciting session and the interesting questions and good feedback.
The official announcement is here.
September 2018
OxyPrem has reached the semifinals in the pitching battle of Startup Days 2018.
This puts OxyPrem on par with the English national team.
September 2018
OxyPrem has successfully achieved participation in the VentureLab AIT India programme.
We will take part in a one-week visit to India in December to meet clinicians and industry partners.
August 2018
We are now part of Switzerland's well known Venture Kick programme.
Our team successfully completed the stage I pitch and will soon be heading for the "kickers camp" to prepare for stage II and exchange ideas with other founders.
The official announcement is here.
May 2018
The UZH Annual Media Conference has brought about some press coverage:
For example
here,
here,
here,
here,
here, and
here.
A big thank you to all the journalists for the interesting questions and the good reporting!
April 2018
The OxyPrem team is heading for Stuttgart to establish production partnerships.
Please contact us to get in touch at the event.
Find additional information here:
Medtec Europe, Stuttgart 2018
February 2018
The OxyPrem team has started a collaboration with Zurich-based Therapy Development Accelerator (TDA).
The TDA expert team offers a wide range of knowledge, infrastructure, and services to push partnering projects forward.
Visit the TDA website for more information.
February 2018
Project OxyPrem is now part of the UZH BioEntrepreneur Fellowship program by the University of Zurich.
Find additional information here:
Fellowship information
List of Fellows
Aug 2017
OxyPrem will be part of this year's Rising Stars Start-Up Showcase of the Sachs MedTech & Digital Health Forum in Basel, Switzerland on Sep 25th, 2017.
Find additional information here:
5th Annual MedTech & Digital Health Forum
Regulatory Affairs and Quality Manager
CTO
R&D Specialist
Software Engineer
CEO
Product Designer
Lead Product Development
Customer Relations
Business Manager
CMO
Cloud Architect
Clinical Trials and PMS Manager
Chairman of the Board
NOTE: OxyPrem is not involved in the organisation of the SafeBoosC-III trial, but provides equipment for multiple participating hospitals. For any questions related to the SafeBoosC-III trial, please contact the SafeBoosC consortium directly via this E-Mail link.
To randomise babies in the SafeBoosC-III trial, please go to this link to Open Clinica.
